
Insulet Investors Face August 31 Deadline in Securities Fraud Lawsuit
Investors in Insulet Corporation have until August 31, 2026, to seek lead plaintiff status in a class action lawsuit filed in the U.S. District Court for the District of Massachusetts. The litigation follows allegations that the medical device manufacturer misrepresented the safety and manufacturing quality of its Omnipod insulin delivery systems.
























